The company's primary businesses include[citation needed] As of 2024, the Chairman and CEO of OPKO is Phillip Frost.

In May 2022, OPKO Health announced the acquisition for $300 million of U.S based Biotechnology firm, ModeX.

[3][citation needed] On September 7, 2018, the SEC filed a lawsuit against a number of individuals and entities including Opko Health and the CEO and Chairman, Phillip Frost.

Frost entered into settlements with the SEC, which, upon approval by the court in January 2019, resolved the claims.

Without admitting or denying any of the allegations, the company agreed to an injunction from violations of Section 13(d) of the “Exchange Act”, a strict liability claim, and to pay a $100,000 penalty, which has been paid.